Economic evaluations of radioembolization with yttrium-90 microspheres in liver metastases of colorectal cancer: a systematic review

Table 4 Descriptive analysis of partial economic evaluations for liver metastases from colorectal cancer (lmCRC)

Author, year, publication type and country	Patient’s characteristic	Treatments		Analysis type/Clinical source	Perspective/Time horizon	Outcomes
Author, year, publication type and country	Patient’s characteristic	Comparators	Microspheres	Analysis type/Clinical source	Perspective/Time horizon	Outcomes
Fusco, 2017 [28] Communication at congress United Kingdom	lmCRC not suitable for resection/ablation; chemotherapy-naïve (First line treatment) ^a	Y-90 TARE + FOLFOX vs. FOLFOX	Y-90 resin microspheres	CA / FOXFIRE clinical trial	Payer/ 3 years	Direct cost (medical) on Primary care resource. QoL
Dhir, 2018 [29] Original article USA	lmCRC liver-only unresectable (Second line treatment) ^b	Y-90 TARE + MDR vs. HAI + MDR	ND	CA / Retrospective study	Payer/ 2 years	Direct cost (medical) estimated retrospectively by the consumption of hospital resources. OS

HAI: hepatic artery infusion (pump) with floxuridine, FOLFOX: folinic acid, fluorouracil and oxaliplatin, lmCRC: liver metastases from colorectal cancer, OS: overall survival, QoL: quality of life, MDR: multi-drug regimens including oxaliplatin and/or irinotecan ± biological treatments, Y-90 TARE: transarterial radioembolization with yttrium 90
a. Chemotherapy-naïve metastatic colorectal cancer patients with liver metastases. The sample size reported in this analysis considered the clinical trial data from FOXFIRE study [36] (N = 364), and then specified patients treated according to Wasan et al. 2017 [40] (Y-90 TARE + FOLFOX n = 167; FOLFOX n = 169). b. Pre-treated patients with a heavy liver tumour burden (median of 10 lesions and almost 40% of liver parenchymal replacement by tumour). The sample size reported in this analysis considered the clinical data from Dhir et al. 2018 [29] study (Y-90 TARE n = 49; HAI n = 48)

ISSN: 1471-230X